D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT)

Equities research analysts at D. Boral Capital began coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital’s target price suggests a potential upside of 183.91% from the stock’s current price.

A number of other research analysts also recently commented on CKPT. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Down 0.9 %

CKPT stock opened at $3.17 on Monday. The company has a market cap of $154.80 million, a price-to-earnings ratio of -1.72 and a beta of 1.36. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The business has a 50 day moving average price of $3.63 and a two-hundred day moving average price of $2.88.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities research analysts anticipate that Checkpoint Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares in the company, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 220,230 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the completion of the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at $10,797,690.54. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CKPT. Virtu Financial LLC acquired a new stake in shares of Checkpoint Therapeutics during the third quarter worth $30,000. XTX Topco Ltd bought a new position in Checkpoint Therapeutics during the second quarter worth about $34,000. Gladstone Institutional Advisory LLC raised its stake in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 20,500 shares in the last quarter. Magnus Financial Group LLC boosted its holdings in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 4,000 shares during the period. Finally, Choreo LLC grew its position in shares of Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.